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Summary Fifty-one children, aged from 15 months to 13 years 5 months with metastatic neuroblastoma
presenting sequentially at the participating institutions received four 3 to 4 weekly courses of high dose
multiagent chemotherapy. High dose cisplatin (200mg m2) combined with etoposide (500mgm2), HIPE,
was alternated with ifosfamide (9 g m2), vincristine (1.5 mg m2), and adriamycin (60mg m-'), IVAd.
Disease status was re-evaluated 3 to 4 weeks after the fourth course and the response classified according to
the International Neuroblastoma Response Criteria (INRC). The overall response rate in evaluable patients
was 55% and response rates by site were: bone marrow 67% (complete response 47%); bone scan 68%;
primary tumour 61%, and urinary catecholamine metabolites (VMA/HVA) 95%. Serial 51Cr EDTA renal
clearance studies showed a glomerular filtration rate (GFR) decline in 40% of patients but in only seven cases
to below 50% of the pretreatment value. There was no instance of renal failure during induction, though two
patients developed severe renal failure following 'megatherapy' given to consolidate remission. Serial
audiometry showed a significant decline in hearing at frequencies above 2,000 Hz in 37% of children but at or
below 2,000 Hz in only 17%. Neutropenia and thrombocytopenia were severe and intravenous antibiotics were
required after 30% of courses. Each of two treatment-related deaths occurred during pancytopenia following
courses of IVAd. Complete, or greater than 90%, removal of primary site tumour was possible in 70% of
cases following this induction regimen and 75% ofpatients proceeded to elective megatherapy within a median
time of 24 weeks after diagnosis. This short intensive induction programme is highly effective at achieving
cytoreduction, enabling early surgery and early megatherapy procedures. It is, however, too early to draw firm
conclusions about the impact of this approach to treatment on the cure rate.
The management of metastatic neuroblastoma in children
over one year of age remains one of the most frustrating
areas of paediatric oncology. Early chemotherapy regimens
based on cyclophosphamide, adriamycin and vincristine
achieved responses but very few long-term survivors. Progres-
sion-free survival beyond 3 years was around 10%. (Ninane
et al., 1981; Finklestein et al., 1979; Nitschke et al., 1980).
The addition of other agents such as mustine and DTIC had
little impact (Rosen et al., 1984). The introduction of VM26
and cisplatin improved the initial remission rate (Hayes et al.,
1981). Regimens based on this combination are now widely
used and with surgery to the primary site complete remission
rates in the region of 60% are achieved. However, long-term
survival still remains around 20% at best (Rosen et al., 1984;
Shafford et al., 1984; Bernard et al., 1987; Kushner et al.,
1987). 'Megatherapy' procedures, using agents such as high
dose melphalan, total body irradiation, or other chemo-
therapy combinations with bone marrow rescue, prolong
progression-free survival but have only had a marginal
impact on the cure rate. To date, the most optimistic reports
describe progression-free survival rates of around 30% at 3
years (Pinkerton et al., 1987; Philip et al., 1987; Hartmann et
al., 1987).
From the high early relapse rate, it is clear that in even
so-called complete responses, there is considerable undetected
residual diseasae. One approach to improve initial cytoreduc-
tion is by escalation of the dose of the drugs currently
available. In two separate studies by the European Neuro-
blastoma Study Group (ENSG) ifosfamide as a single agent
(ENSG 3A) (Kellie et al., 1988) and high dose cisplatin/eto-
poside combination (ENSG 3B) (Hartmann et al., 1988) were
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evaluated in untreated patients with advanced neuroblas-
toma. The toxicity of these regimens was found to be accept-
able and the response rates were 44% and 70%, respectively.
In ENSG 3C these agents were combined with vincristine
and adriamycin in a regimen designed to administer the
maximum amount of drug tolerable as 3 to 4 weekly pulses
over a short period. The aim was to determine if this app-
roach would improve the complete response rate by com-
parison with lower dose regimens.
Patients and methods
Fifty-one unselected patients presenting sequentially between
January 1986 and November 1987 to the participating cen-
tres and diagnosed to have Stage IV neuroblastoma, Evans
and INSS classification (Brodeur et al., 1988), were included
in this study.
Age at presentation ranged from 15 months to 13 years 5
months (median 38 months) and there were 31 boys. Staging
investigations are listed in Table I and included bone marrow
aspirates and trephines, radioisotope bone scan, abdominal
ultrasound and/or CT scan, and measurement of urinary
catecholamine metabolites, VMA and HVA. Sites of initial
disease are given in Table II. The chemotherapy regimens
HIPE and IVAd with fluid and electrolyte supplementation
are shown in Table III. A total of four courses was given
with an interval of 21 to 28 days, or as soon as the blood
count had recovered.
Disease status was fully re-assessed 3 to 4 weeks after the
fourth course of therapy using the same investigations as at
diagnosis. Marrow re-evaluation involved at least four sites,
including a minimum of two trephine biopsies. MIBG scans
performed in nine patients before and after therapy are not
included in the formal definition of response according to
current INSS guidelines. Serial serum electrolytes, including
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Table I Schema for evaluation of response and toxicity
After one
cycle of 4 weeks after
Pretreatment HIPE/IVAD 2nd cycle
Bone Marrow aspirates x x x
& trephines
Urine VMA x x x
HVA
9Tc Bone scan x x
CT scan/ultrasound x x x
Audiometry x x x
5"Cr EDTA GFR x x x
MIBG scan x x
Table II Extent ofdisease at presentation
Urine catecholamines Bone
Primary site VMA HVA Bone marrow Othera
Adrenal 42 41 raised 26 raised 41b+ 47 + 9
Pelvis 2 7 normal 8 normal 9 - 4 -
Thorax 6 3 NE 17 NE I NE
Thoraco- 1
abdominal
aSubcutaneous, liver, distant nodes; b9 evaluated only with mIBG
scan.
magnesium, calcium and phosphate, liver enzymes, and 51Cr
EDTA GFR were monitored throughout therapy.
Audiography was done in 30 patients. In 26 children old
enough to co-operate, formal audiograms were obtained,
whilst in four younger children, hearing was evaluated by the
Kendall toy test. To standardize audiographic evaluation, the
scoring system devised by Brock et al. (1988) was used (Table
IV). Myelosuppression, transfusion requirements, treatment
for infection and weight loss were also documented.
Table I shows the overall schema of the study. Response
was classified (Table V) according to the International
Neuroblastoma Staging System (Brodeur et al., 1988).
Results
The median duration of chemotherapy, start of course 1 to
start of course 4, was 78 days (range 68-88 days). The
median interval between courses of chemotherapy was 26
days following HIPE (range 21-28 days) and 24 days after
IVAd (range 17-60 days).
Table IV Extent ofhearing loss after 2 courses ofHIPE (400mgm-2
cisplatin): 30 patients were fully evaluated
Grade ofhearing Number of
deficita Deficit hearing loss patients
0 [None] <40dB at any frequency 14
1 [Mild] ) 40dB at 8000 Hz 6
2 [Moderate] >40dB at 4000 Hz 5
3 [Marked] >40dB at 2000 Hz 5
4 [Severe] >40dB at 1000 Hz 0
aBrock et al., 1988.
Response
Responses to chemotherapy, site by site, are listed in Table
VI. These evaluations were done after four courses ofchemo-
therapy before surgical removal of the primary tumour,
except in five patients where the tumour was resected at
diagnosis or after a single course. Four patients were not
evaluable for response; three due to early death, one disease-
related who died with PD after three courses and two
treatment-related. One child had no response to the first
course of treatment and was taken off the study. The res-
ponse rates were respectively; bone marrow 67% (24/36) with
complete responses (CR) 47% (17/36); bone 68% (17/25) with CR 16% (4/25); catecholamines 91% (39/43) with CR
44%; primary tumour 61% (22/36) with CR 3%.
Using INSS criteria, the overall response rate was 55%
(26/47) with a mixed response (MR) in a further 40% (19).
In nine of these there was a failure to respond at one site
with responses at each other evaluable site. If no patients are
excluded, that is, including toxic deaths and early PD, overall
response rate was 51%.
In four patients only three marrow sites were reported,
often due to crush artefact. By strict INSS criteria these are
not evaluable for response. Three were negative at each site
studied and, if these four results were included, it would
increase the marrow CR rate to 50%. As expected, marrow
involvement at reassessment was patchy and confirms the
need for examining several sites. One out offour was positive
in seven cases, the partial responders; of the non-responders,
only three were positive at all sites, the other nine had 2 or 3
positive out of 4. In most (10/18) of the mixed responses,
there was residual marrow involvement despite partial or
complete responses at other sites. In each of these at least
two sites were positive. By strict INSS criteria some of these
cases are unclassifiable (Table V). They fall between a partial
response (PR), which is not possible as two or more marrows
are positive, and a mixed response (MR), which is also
Table III Drug dose, hydration and electrolyte regimens
HIPE IVAD
Day 0 1 2 3 4 5 6 b21 22 23 Hydrationa < > Ifosfamide + 4 +
3gm-2 over 1 hr
CDDP 49 4 4 49 + MESNAC
40mg m-2 over 3gm-2 24 hr-' 1-Il 1 hr in 3% NaCl
Etoposide i, 4 4 + + Vincristine
lOOmgm-2 over 1.5mgmM2 +
1 hr
Adriamycin +
60mgm2
MgSO450%1.6ml1'
aDaily 3 1 m-2 0.9% NaCl + KCI 20 mmol 1-'
calcium gluconate 10% 3 ml 1'
bdelayed until neutrophils > 1.0 x I0 1'- and platelets >100 x 1091-; CMESNA + hydration - 0.9% NaCl + 20 mmol KCI 1-lat 3 1 m-2 continued for 24 hr after last ifosfamide dose.CHEMOTHERAPY IN NEUROBLASTOMA 321
Table V Definitions of response to chemotherapy: international neuroblastoma res-
ponse criteria
Metastases
No tumour (chest, abdomen, liver,
bone, bone marrow, nodes, etc.)
VGPR Reduction No tumour (as above except bone);
>90% but < 100% no new bone lesions, all pre-existing
lesions improved
PR Reduction
50-90%
50-90% reduction in measurable
sites; 0-1 bone marrow samples with
tumour; bone lesions same as VGPR
Markers
HVA; VMA
normal
HVA; VMA
decreased
>90%
HVA; VMA
decreased
50-90%
MR > 50% reduction of any measurable lesion (primary or metastates) with
<50% reduction in any other; no new lesions; <25% increase in any
existing lesion (exclude bone marrow evaluation)
NR No new lesions; <50% reduction but <25% increase in any existing
lesion (exclude bone marrow evaluation)
PD Any new lesion; increase of any measurable lesion by >25%; previous
negative marrow positive for tumour
'CR = Complete Response; VGPR = Very Good Partial Response; PR = Partial
Response; MR = Mixed Response; NR = No Response; PD = Progressive Disease.
Table VI Response at individual sites
Primary tumour VMA±HVA Bone scan Bone marrow Other sites
(n = 36) (n = 41) (n = 25) (n = 36) (n = 9)
CR 1 19 4 17 7
PR 21 20 13 7 2
NR 13 2 5 12 -
PD 1 0 3* - -
Non
Evaluablea 15 10 26 15 38
6 not measured 1 not measured 11 not done 4 normal at diagnosis 36 no other site
5 early resection 5 normal at 11 normal at I pooled aspirate (-) 2 not measured
diagnosis diagnosis 2 inadequate samples
4 only 3 samples
-1 1/3(+)
- 3 0/3 ( + )
aincludes 3 early deaths 1 off study due to PD after 1 course.
Overall Responses: CR 2 (both had early resection ofprimary)
VGPR 1
PR 23
MR 19
PD 4 (2 prior to formal re-evaluation)
(MR) not possible as the marrow is excluded and the res-
ponse at other sites is PR. On balance MR seems most
appropriate.
Only 25 patients were re-evaluated by bone scan. Eleven
had been negative at diagnosis but of the other 11, 9 were
re-assessed with mIBG alone. There were 4 CR and 5 PR.
Surgical intervention was usually after the fourth course or
in some patients a further course of either IVAd or HIPE
was given. In 55% of patients, there was complete micro-
scopic removal of the primary tumour and in a further 15%
more than 90% was removed.
Patients who achieved at least a partial remission with no
or minimal residual marrow disease proceeded to elective
megatherapy. This was not possible in only three because of
early disease progression. The median time from diagnosis to
megatherapy was 24 weeks (range 14-40 weeks).
Toxicity
The GFR fell in 12 of the 29 patients who were prospectively
and serially evaluated; the median decline was 30% (range
5%-50%). After completion of HIPE/IVAd in 36 patients
GFR was less than 100 ml min-' 1.73 m2 in 11 (37%), and
less than 70 in 3 (9%). There was no elevation of urea or
creatinine during induction chemotherapy but, in two cases
acute renal failure followed megatherapy with melphalan and
TBI. High dose platinum and possibly high dose ifosfamide
may have contributed to poor renal function in these two
cases but the premegatherapy GFRs were 65 ml and 94ml
min-' 1.73 m-2 respectively.
The incidence of infections and the need for platelet trans-
fusions are listed in Table VII and were, as expected, con-
siderably higher than with lower dose treatments. There were
only two treatment-related deaths during induction, both due
to a combination of sepsis and severe electrolyte disturbance
following IVAd courses. Electrolyte disturbances following
treatment are shown in Table VII. Hypomagnesaemia occur-
red but the severity was limited by the prophylactic administ-
ration of magnesium during high dose platinum therapy. Ten
out of thirty evaluable patients had moderate to severe high
tone hearing loss after four courses of treatment (Table IV).
Most patients proceeded to megatherapy after surgical
resection of primary tumour. In most cases no further
chemotherapy was given in the interval, although some poor
responders received further IVAd after the formal re-evalua-
tion at week 12.
Megatherapy regimens varied widely between centres with
combinations of melphalan, carmustine, teniposide, vincris-
tine, cisplatin and total body irradiation (TBI). In some
patients double procedures were performed (Philip et al.,
1987; Hartmann et al., 1987). Some units purged marrow
with monoclonal antibody or Asta Z. It is therefore im-
possible to draw conclusions about the effect of high dose
induction chemotherapy on subsequent bone marrow graft
function or general toxicity.
There were, however, four treatment-related deaths follow-
aResponse Primary
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Table VII Toxicity ofchemotherapy
Weight Loss
Biochemical abnormalities
Myelosuppression:
Duration of neutropenia
<0.5 x 1091I-'
Febrile episode requiring
intravenous antibiotics
Incidence of platelets
<50x 109l-'
Other toxicities
Post HIPE
Post IVAD
Range 0-2.5 kg (median 0.6 kg)
HC03 (<18mEql ') (16/37)
Mg (<0.7 mEq 1- ) (6/38)
HIPE
1-4 (med 7) days
20% of courses
25% of courses
(8 required
transfusion)
Severe diarrhoea
(WHO Gd 3/4)
encephalopathy
seizures
somnolence
haematuria
tubulopathy
reversible cardiac
failure
fatal septic shock
IVAD
1 - 15 (med 6) days
10% of courses
10% of courses
(4 required
transfusion)
6 patients
2 patients
1 patient
2 patients
3 patients
1 patient
2 patients
2 patients
ing megatherapy, which is not significantly higher than seen
after other induction regimens.
Discussion
In the HIPE/IVAd regimen both dose escalation and alter-
nating, potentially non-cross resistant regimens of chemo-
therapy are used in an attempt to prevent chemo-resistance.
Its toxicity is severe but tolerable and relatively high remis-
sion rates are achieved after only four courses. Detailed
comparisons of response rates with other regimens is difficult
owing to lack of standardized definitions. It is almost mean-
ingless to quote marrow CR rates in previous studies where
only aspirates, often single, have been used for reassessment.
Because of the patchy infiltration often seen in metastatic
neuroblastoma, techniques of re-assessing patients in this
study have been relatively stringent with an attempt at stan-
dardization between centres. A minimum of four bone mar-
row sites, including at least two trephines, was a prerequisite
for assessment of marrow response. Similarly, at least two
dimensional measurements of disease were required to draw
conclusions about response at the primary site. Three dimen-
sional measurements are recommended by the INSS but this
was not always recorded and may be difficult to determine on
review of imaging, especially with ultrasound. As a staging
tool mIBG imaging remains, to some extent, experimental
(Pritchard et al., 1988). A number of European centres have
now replaced technetium bone scanning with this technique
but it has not yet been incorporated in the INSS.
Complete response rates in marrow with other recently
reported platinum-containing regimens given over several
months are somewhat higher; 70% with PE-CADO (Bernard
et al., 1987) or N4SE (Kushner et al., 1987) and 66% with
OPEC (Shafford et al., 1984) for Stage IV patients aged over
one year at diagnosis. Sufficient response data are published
for PE-CADO (Bernard et al., 1987) and by INSS criteria the
overall response rate was 80%. Only one of 33 patients failed
to achieve PR at the primary site. It is apparent, therefore,
that in some patients marrow response may be slow and CR
is achieved after more prolonged therapy. Similarly, further
shrinkage of disease elsewhere occurs over several weeks. It is
not clear to what extent adding IVAd to HIPE increases
effectiveness as with HIPE alone in the pilot study (ENSG
IIIb) the CR rate in marrow was 40% after only eight weeks
treatment (Hartmann et al., 1988).
The dose of cisplatin used in this study (200 mg m-2
divided over five days) appears to be the maximum tolerable.
Attempts to escalate beyond this level have been associated
with unacceptable intestinal toxicity (Clerico et al., 1987).
The renal and auditory toxicity is comparable to that of the
same total dose of platinum given over 8 to 10 courses
(Shafford et al., 1984). Although a third course is within the
limits of renal tolerance, high tone hearing loss extends
towards the normal hearing range. It is possible that, using a
continuous infusion regimen, the number ofcourses tolerated
can be increased (Castello et al., in press). Etoposide has
been shown to be more active when given in a divided dose
regimen in small cell lung cancer (Cavalli et al., 1978) and
although doses up to 2.4 gm2 as single agent have been
used in leukaemia (Bostrom et al., 1987), in combination
with high dose platinum the dose of 500 mgm-2 approaches
the limits of acceptable myelotoxicity. The dose ofifosfamide
is near the maximum used in phase II paediatric studies
(Pinkerton et al., 1985; de Kraker et al., 1984) and has been
found to be active in neuroblastoma and paediatric sarcomas
either alone or in combination with agents such as etoposide
or cisplatin (Pratt et al., 1986). At high doses central nervous
system and renal tubular toxicities are limiting factors. With
a cumulative dose of only 120mgm2 adriamycin-related
cardiotoxicity should not be a problem so it is worrying that
two patients showed evidence of cardiac dysfunction. The
possibility of ifosfamide contributing to anthracycline toxicity
has recently been raised (Oberlin et al., 1988).
The use of supposedly non-cross resistant regimens in an
alternating sequence has gained popularity in cancer chemo-
therapy. There is some evidence that high dose platinum/
etoposide is effective in patients who have failed to respond
to regimens containing cyclophosphamide (Philip et al.,
1987), but any advantage due to this method of scheduling in
neuroblastoma remains theoretical. Whether ifosfamide is
superior to cyclophosphamide is also debatable (Oberlin et
al., 1988; Jurgens et al., 1988) and although improved res-
ponse rates in rhabdomyosarcoma and Ewing's sarcoma have
been claimed (Treuner et al., 1987; de Kraker et al., 1987),
there is yet no randomized study in neuroblastoma or any
other paediatric tumour. The beneficial effect of dose escala-
tion of cyclophosphamide in neuroblastoma has been clearly
shown (Kushner et al., 1987) and the lower myelotoxicity of
ifosfamide enables a higher dose to be given. The response
rate to ifosfamide alone in relapsed neuroblastoma was
disappointing (de Karker et al., 1987), but direct comparison
with single agent cyclophosphamide is not possible because
such studies were done in the 1960s when virtually no
attempt at objective response measurement was made. Alter-
native treatment strategies to improve response rates are
under investigation, for example, a United Kingdom Child-
ren's Cancer Study Group (UKCCSG) phase II study of
MIBG linked '1'I therapy is in progress.
In conclusion, the HIPE/IVAd regimen is a short, effective
induction regimen enabling early consolidation with mega-
therapy procedures. The overall complete response rate was
not better than that achieved with similar total drug doses
given over a more prolonged period but the impact of achiev-
ing a response earlier awaits further follow up. Further in-
crease in dose intensity with administration of cisplatin at
day 10 between courses of combination chemotherapy is also
being evaluated (Pearson et al., 1988) and such a 'rapid
delivery high dose intensity' schedule will be the subject of
the next ENSG randomized trial.
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